219 related articles for article (PubMed ID: 16119673)
1. The prevalence and clinical significance of antiphospholipid antibodies in the patients with systemic sclerosis--preliminary report.
Sulik A; Kowal-Bielecka O; Domysławska I; Chwiećko J; Sierakowski S
Rocz Akad Med Bialymst; 2005; 50 Suppl 1():228-31. PubMed ID: 16119673
[TBL] [Abstract][Full Text] [Related]
2. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis.
Marie I; Jouen F; Hellot MF; Levesque H
Br J Dermatol; 2008 Jan; 158(1):141-4. PubMed ID: 18028496
[TBL] [Abstract][Full Text] [Related]
3. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
Lopez LR; Simpson DF; Hurley BL; Matsuura E
Ann N Y Acad Sci; 2005 Jun; 1051():313-22. PubMed ID: 16126973
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.
Mimura Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
Br J Dermatol; 2004 Oct; 151(4):803-8. PubMed ID: 15491420
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
[TBL] [Abstract][Full Text] [Related]
6. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
Nishijima C; Sato S; Takehara K
J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
[TBL] [Abstract][Full Text] [Related]
7. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
8. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
9. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.
Komura K; Yanaba K; Ogawa F; Shimizu K; Takehara K; Sato S
Clin Exp Dermatol; 2008 May; 33(3):329-32. PubMed ID: 18312458
[TBL] [Abstract][Full Text] [Related]
10. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
11. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
[TBL] [Abstract][Full Text] [Related]
12. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
[TBL] [Abstract][Full Text] [Related]
13. Association of anti phosphatidyl ethanolamine antibodies and low complement levels in systemic sclerosis patients--results of a cross-sectional study.
Bălănescu P; Lădaru A; Bălănescu E; Băicuş C; Dan GA
Scand J Clin Lab Invest; 2015 Oct; 75(6):476-81. PubMed ID: 26067612
[TBL] [Abstract][Full Text] [Related]
14. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
[TBL] [Abstract][Full Text] [Related]
15. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.
Mitri GM; Lucas M; Fertig N; Steen VD; Medsger TA
Arthritis Rheum; 2003 Jan; 48(1):203-9. PubMed ID: 12528120
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients.
Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y
Arthritis Rheum; 2006 Jul; 54(7):2243-9. PubMed ID: 16802363
[TBL] [Abstract][Full Text] [Related]
17. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.
Danowski A; Kickler TS; Petri M
J Rheumatol; 2006 Sep; 33(9):1775-9. PubMed ID: 16960938
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients.
Roussel V; Yi F; Jauberteau MO; Couderq C; Lacombe C; Michelet V; Gil R; Couratier P; Vallat JM; Preud'homme JL
J Autoimmun; 2000 May; 14(3):259-65. PubMed ID: 10756088
[TBL] [Abstract][Full Text] [Related]
19. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome.
Marai I; Gilburd B; Blank M; Shoenfeld Y
Hum Antibodies; 2003; 12(3):57-62. PubMed ID: 14646033
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis.
Sobanski V; Lemaire-Olivier A; Giovannelli J; Dauchet L; Simon M; Lopez B; Yelnik C; Lambert M; Hatron PY; Hachulla E; Dubucquoi S; Launay D
Front Immunol; 2018; 9():2457. PubMed ID: 30464761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
